| Deal value | $20M |
|---|---|
| Share of market cap | 8.4% |
| Share of annual revenue | 343.6% |
Key highlights
- Acquisition of APT-1011 (now ABO-801) for $20 million in upfront equity consideration
- Deal structured with no upfront cash, issuing 4,494,383 common shares to the seller
- Eligible for $30 million upon FDA approval and $30 million in sales milestones
- ABO-801 is a once-daily oral disintegrating tablet with FDA Orphan Drug designation
- Planned initiation of a new Phase 3 clinical study in the second quarter of 2027
Deal Structure & Terms
Abeona Therapeutics issued 4,494,383 shares of common stock to Ellodi Pharmaceuticals to satisfy the twenty million dollar upfront consideration, avoiding any immediate cash outlay. The transaction includes substantial contingent liabilities, with Ellodi eligible to receive thirty million dollars upon the successful FDA approval of a New Drug Application and an additional thirty million dollars upon reaching specific sales targets. Tiered royalties ranging from the low to mid-teens will also be paid on net sales. The upfront shares are subject to a staggered lock-up agreement, with one-third of the equity released at six, twelve, and eighteen-month intervals following the closing date.
Strategic Rationale
- Targets eosinophilic esophagitis, a chronic inflammatory disease affecting approximately 360,000 diagnosed patients in the U.S.
- Adds a candidate with existing FDA Orphan Drug and Fast Track designations to the pipeline
- Utilizes a specialized oral disintegrating tablet formulation to provide topical esophageal delivery with low systemic exposure
- Leverages data from two previous Phase 3 trials involving 361 patients to optimize future study design
- Transitions the company toward a diversified commercial-stage profile with multiple value inflection points
Clinical Timeline & Roadmap
ABO-801 has undergone extensive clinical evaluation, including a Phase 2b dose-ranging study and two completed Phase 3 trials. While the previous late-stage studies did not meet their primary symptom-related endpoints, they achieved statistically significant results in endoscopic and histologic measures. Abeona plans to utilize these insights to launch a newly designed Phase 3 study in the second quarter of 2027. Under the current development timeline, the company expects to report topline results from this pivotal trial by the end of 2028, supported by ongoing data from an Expanded Access Program that has served over 260 participants.
Management Perspective
“The acquisition of ABO-801 is an important step in building Abeona into a diversified commercial-stage company with multiple opportunities for value inflection, adding an asset with substantial revenue potential in a rapidly growing disease.”
Financial & Market Context
- Concurrently announced a $30 million private placement financing with leading life sciences investors
- Recent $155 million sale of a Priority Review Voucher in May 2025 significantly strengthened the balance sheet
- Management previously guided for at least 12 months of cash runway as of August 2026
- Targeting a ramp-up in commercial manufacturing capacity to 10 runs per month by year-end 2026
Down 37.6% since our story on 9 Nov: $4.17 when we broke it → $2.60 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $4.41 |
|---|---|
| 20 Oct | $4.60 |
| 21 Oct | $4.51 |
| 22 Oct | $4.47 |
| 23 Oct | $4.40 |
| 26 Oct | $4.31 |
| 27 Oct | $4.45 |
| 28 Oct | $4.55 |
| 29 Oct | $4.56 |
| 30 Oct | $4.35 |
| 2 Nov | $4.25 |
| 3 Nov | $4.25 |
| 4 Nov | $4.22 |
| 5 Nov | $3.91 |
| 6 Nov | $4.17 |
| 9 Nov | $2.54 |
| 10 Nov | $2.46 |
| 11 Nov | $2.30 |
| 12 Nov | $2.29 |
| 13 Nov | $2.42 |
| 16 Nov | $2.60 |
| Date | Announcement | Amount |
|---|---|---|
| 12 May 2025 | Sale of Rare Pediatric Disease Priority Review Voucher (PRV)Source: SEC filing | $155.0 Million |
Management commentary
“The acquisition of ABO-801 is an important step in building Abeona into a diversified commercial-stage company with multiple opportunities for value inflection, adding an asset with substantial revenue potential in a rapidly growing disease.”
“We have strong conviction in the team and the opportunity and believe ABO-801 has the potential to offer a differentiated profile in EoE, supported by once-daily dosing and low systemic exposure.”
| Share price | $4.17 |
|---|---|
| Market cap | $238M |
| Revenue (annual) | $6M |
| 1-month price change | -17.91% |
| Sector | HealthcareBiotechnology |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by Abeona Therapeutics Inc. announcing the acquisition of assets from Ellodi Pharmaceuticals.
Track ABEONA THERAPEUTICS INC. live
Get the next ABEONA THERAPEUTICS INC. SEC filing seconds after it lands.



